Cargando…

Delivery of therapeutic small interfering RNA: The current patent-based landscape

Implementing small interfering RNA (siRNA) is a promising therapy because it silences disease-related genes theoretically. However, the efficient delivery of siRNA is challenging, which limits its therapeutic applications. Various pharmaceutical delivery systems containing key technologies have been...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu, Xiong, Shi-Hang, Li, Fei, Kong, Xiang-Jun, Ouyang, De-Fang, Zheng, Ying, Yu, Hua, Hu, Yuan-Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263868/
https://www.ncbi.nlm.nih.gov/pubmed/35847171
http://dx.doi.org/10.1016/j.omtn.2022.06.011
_version_ 1784742844271951872
author Chen, Yu
Xiong, Shi-Hang
Li, Fei
Kong, Xiang-Jun
Ouyang, De-Fang
Zheng, Ying
Yu, Hua
Hu, Yuan-Jia
author_facet Chen, Yu
Xiong, Shi-Hang
Li, Fei
Kong, Xiang-Jun
Ouyang, De-Fang
Zheng, Ying
Yu, Hua
Hu, Yuan-Jia
author_sort Chen, Yu
collection PubMed
description Implementing small interfering RNA (siRNA) is a promising therapy because it silences disease-related genes theoretically. However, the efficient delivery of siRNA is challenging, which limits its therapeutic applications. Various pharmaceutical delivery systems containing key technologies have been developed and patented, which are of great concern to developers in the field. Despite numerous studies devoted to siRNA-delivery technologies, few researchers have systematically examined relevant patents. Patents, as bridges connecting academic progress with applicable innovation, encapsulate cumulative technological innovations and provide valuable information for academic research and commercial development. This study aims to analyze advances in therapeutic siRNA delivery technology from a patent perspective. A total of 11,509 patent documents from 3,309 patent families were collected, classified into 10 technological categories, and comprehensively analyzed. An overall patent landscape of siRNA delivery was presented from the temporal, spatial, organizational, and technological dimensions. This work is expected to help researchers and developers in the field of siRNA delivery form a basis for decision-making by combining our findings with supplementary data.
format Online
Article
Text
id pubmed-9263868
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-92638682022-07-14 Delivery of therapeutic small interfering RNA: The current patent-based landscape Chen, Yu Xiong, Shi-Hang Li, Fei Kong, Xiang-Jun Ouyang, De-Fang Zheng, Ying Yu, Hua Hu, Yuan-Jia Mol Ther Nucleic Acids Original Article Implementing small interfering RNA (siRNA) is a promising therapy because it silences disease-related genes theoretically. However, the efficient delivery of siRNA is challenging, which limits its therapeutic applications. Various pharmaceutical delivery systems containing key technologies have been developed and patented, which are of great concern to developers in the field. Despite numerous studies devoted to siRNA-delivery technologies, few researchers have systematically examined relevant patents. Patents, as bridges connecting academic progress with applicable innovation, encapsulate cumulative technological innovations and provide valuable information for academic research and commercial development. This study aims to analyze advances in therapeutic siRNA delivery technology from a patent perspective. A total of 11,509 patent documents from 3,309 patent families were collected, classified into 10 technological categories, and comprehensively analyzed. An overall patent landscape of siRNA delivery was presented from the temporal, spatial, organizational, and technological dimensions. This work is expected to help researchers and developers in the field of siRNA delivery form a basis for decision-making by combining our findings with supplementary data. American Society of Gene & Cell Therapy 2022-06-22 /pmc/articles/PMC9263868/ /pubmed/35847171 http://dx.doi.org/10.1016/j.omtn.2022.06.011 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Chen, Yu
Xiong, Shi-Hang
Li, Fei
Kong, Xiang-Jun
Ouyang, De-Fang
Zheng, Ying
Yu, Hua
Hu, Yuan-Jia
Delivery of therapeutic small interfering RNA: The current patent-based landscape
title Delivery of therapeutic small interfering RNA: The current patent-based landscape
title_full Delivery of therapeutic small interfering RNA: The current patent-based landscape
title_fullStr Delivery of therapeutic small interfering RNA: The current patent-based landscape
title_full_unstemmed Delivery of therapeutic small interfering RNA: The current patent-based landscape
title_short Delivery of therapeutic small interfering RNA: The current patent-based landscape
title_sort delivery of therapeutic small interfering rna: the current patent-based landscape
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263868/
https://www.ncbi.nlm.nih.gov/pubmed/35847171
http://dx.doi.org/10.1016/j.omtn.2022.06.011
work_keys_str_mv AT chenyu deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape
AT xiongshihang deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape
AT lifei deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape
AT kongxiangjun deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape
AT ouyangdefang deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape
AT zhengying deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape
AT yuhua deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape
AT huyuanjia deliveryoftherapeuticsmallinterferingrnathecurrentpatentbasedlandscape